Peptides Paired Together
How peptides work together in symphony — each agent covering a distinct lever of metabolism, mitochondria, healing, growth, and fat mobilization.
Metabolic
The Nuclear Stack
Retatrutide + 5-Amino-1MQ — top-down fat mobilization, bottom-up mitochondrial oxidation.
1 + 1 doesn't equal 2, it equals 11. You're going from an old coal motor to a nuclear reactor.
Retatrutide is a triple agonist at GLP-1R, GIPR, and GCGR, coupling to Gs protein to activate adenylyl cyclase and raise cAMP, driving glucose-dependent insulin secretion, delayed gastric emptying, appetite suppression, hepatic thermogenesis, beta-cell restoration, and improved insulin sensitivity. 5-Amino-1MQ is a selective NNMT inhibitor (IC50 ~1.2 μM) that preserves nicotinamide for NAD+ biosynthesis via NAMPT and preserves SAM for methylation, raising cellular NAD+ roughly 34% within 48 hours. Elevated NAD+ activates SIRT1 and SIRT3, which deacetylate and activate PGC-1α to drive mitochondrial biogenesis, while AMPK is engaged to favor fatty acid oxidation. 5-Amino-1MQ also permits selective mTOR signaling — building muscle while suppressing fat storage. Together Retatrutide mobilizes fat and restores signaling top-down while 5-Amino-1MQ ensures the mobilized fat is oxidized in newly-built, NAD+-rich mitochondria bottom-up.
Retatrutide empties the fat stores and restores hormonal signaling from the top down; 5-Amino-1MQ builds the NAD+-rich mitochondrial machinery to burn that fat from the bottom up. The mobilized fuel meets the upgraded engine, and the result is multiplicative rather than additive.
Mitochondrial
Hardware + Software
MOTS-C + 5-Amino-1MQ — install new mitochondrial engines, then upgrade the fuel lines.
MOTS-C installs new engines (mitochondria); 5-Amino-1MQ upgrades the fuel lines and deletes the limiter. It's hardware versus software — and you start printing ATP like the Federal Reserve prints dollars.
MOTS-C is a 16-amino-acid mitochondrial-derived peptide that inhibits the folate cycle at 5-methyltetrahydrofolate, stalling de novo purine biosynthesis so AICAR accumulates roughly five-fold and activates AMPK. AMPK drives GLUT4 translocation, fatty acid oxidation, PGC-1α-mediated mitochondrial biogenesis, mitophagy, and mTORC1 suppression. 5-Amino-1MQ inhibits NNMT to restore NAD+ and activate SIRT1 and SIRT3, which converge on PGC-1α to amplify mitochondrial biogenesis. The two agents hit overlapping but distinct nodes — AMPK and SIRT both feed PGC-1α — so the rebuild signal is reinforced rather than redundant. Together MOTS-C sends the rebuild signal while 5-Amino-1MQ supplies the NAD+ fuel those new mitochondria require.
MOTS-C is the software command to build new mitochondria; 5-Amino-1MQ is the hardware upgrade that delivers NAD+ fuel and removes the NNMT limiter. One writes the program, the other ensures the machine can actually run it.
The Fatigue Stack
Retatrutide + MOTS-C + Methylene Blue — three agents for the three biological failures of fatigue.
Fatigue is a nightclub with three failures happening at once — systemic inflammation, insulin resistance, and ATP shortage. You don't fix the club by addressing one bouncer; you fix all three at the same time.
Dr. Bachmeyer frames fatigue through three biological failures: systemic inflammation, insulin resistance, and ATP shortage. Retatrutide, a triple GLP-1R/GIPR/GCGR agonist, torches liver fat, clears ectopic lipids from muscle mitochondria, and fixes insulin resistance via hepatic thermogenesis and cAMP-driven signaling. MOTS-C mimics exercise through AMPK activation, boosting GLUT4 translocation, restoring insulin sensitivity, and reducing inflammation via PGC-1α-driven mitochondrial biogenesis and mitophagy. Methylene Blue bypasses electron transport chain bottlenecks by accepting electrons from Complex I and shuttling them directly to Complex IV, bypassing leaky Complex I and Complex III, increasing ATP synthesis 30–40% even under stress, with additional anti-inflammatory effects. Together the three agents target all three failures simultaneously rather than sequentially.
Retatrutide clears the metabolic clutter, MOTS-C reboots insulin sensitivity and inflammation, and Methylene Blue forces ATP production past broken electron transport. Each agent covers a failure the others can't, so the stack closes every exit the fatigue was escaping through.
Mitochondrial Stack
MOTS-c + SS-31 — metabolic signaling to rebuild, structural protection to optimize.
Metabolic signaling plus structural protection. MOTS-c tells the cell to rebuild the mitochondria; SS-31 makes sure the new mitochondria actually run clean.
MOTS-c provides metabolic signaling through AMPK activation, driven by AICAR accumulation from folate-cycle inhibition, which promotes GLUT4 translocation, fatty acid oxidation, PGC-1α-mediated mitochondrial biogenesis, and mitophagy. SS-31 (elamipretide) is a cardiolipin-binding peptide that stabilizes inner mitochondrial membrane cardiolipin, preserves electron transport chain supercomplex assembly across Complex I, III, and IV, reduces reactive oxygen species production, and restores oxidative phosphorylation. The two agents address complementary dimensions of mitochondrial health: MOTS-c governs the signaling that calls for new mitochondria, while SS-31 structurally protects and optimizes the mitochondria that get built. Together they cover both the command to rebuild and the structural integrity required for the rebuilt machinery to perform.
MOTS-c sends the metabolic command to build new mitochondria and clear the broken ones; SS-31 binds cardiolipin to keep the electron transport chain supercomplex intact so the new mitochondria produce ATP without leaking ROS. The signal builds, the structure protects, and oxidative phosphorylation is restored.
Healing
Wolverine Protocol
BPC-157 + TB-500 — signal plus scaffold, two-phase tissue repair.
Signal plus scaffold — two-phase repair. BPC-157 builds the vascular supply; TB-500 delivers the cellular scaffold and motility to actually use it.
BPC-157 upregulates VEGF and eNOS to build new capillary beds and modulates NO signaling, FAK-paxillin interactions, and cellular junction stabilization to accelerate angiogenesis and tissue repair. TB-500, the synthetic form of Thymosin β4, sequesters G-actin to maintain a monomeric actin pool for cell migration, promotes cell motility, and delivers repair cells to injury sites. The two agents operate on complementary phases of healing: BPC-157 establishes the vascular supply that oxygenates and nourishes the wound, while TB-500 provides the actin-based motility that lets repair cells actually reach and rebuild the damaged tissue. Together they cover both the supply line and the workforce of repair, producing two-phase healing that neither agent achieves alone.
BPC-157 lays down the vascular supply line — the signal that says 'build blood vessels here' — while TB-500 hands the repair cells the actin scaffold and motility they need to travel and rebuild. Signal without scaffold stalls; scaffold without signal wanders. Together they close the wound.
GH Axis
GH Optimization
CJC-1295 + Ipamorelin — two distinct second-messenger pathways converging on one somatotroph.
Two levers, one pulley. CJC-1295 and Ipamorelin pull the same somatotroph through different second messengers, and the GH release multiplies rather than adds.
CJC-1295 (MOD GRF 1-29 with a Drug Affinity Complex) is a GHRH analog that binds GHRH receptors on pituitary somatotrophs, coupling to Gs to activate adenylyl cyclase, raise cAMP, and engage PKA, stimulating GH synthesis and release. Ipamorelin is a GHRP and ghrelin mimetic that binds the growth hormone secretagogue receptor (GHSR), coupling to Gq to activate PLC, generate IP3, release intracellular calcium, and engage PKC, triggering GH vesicle exocytosis. The two pathways converge on the same somatotroph cells through distinct second messengers — cAMP/PKA versus calcium/PKC — so they amplify rather than compete. The result is roughly 2.5–3× synergistic GH release compared with either peptide alone, with downstream IGF-1 elevation supporting anabolic and recovery effects.
CJC-1295 primes the somatotroph through cAMP and PKA — turning up GH synthesis — while Ipamorelin fires the calcium/PKC trigger that releases the vesicles. One builds the ammunition, the other pulls the trigger, and the same cell answers both calls at once.
Fat Loss
The 3-Lever Fat Loss/Muscle Stack
Retatrutide + Tesamorelin — fat loss and lipolysis on independent levers, muscle preserved.
This is David Copperfield magic — and the slow IV drip glucose myth from Instagram is exactly that, a myth. The two processes don't interfere because they operate on different physiology.
Tesamorelin is a synthetic 44-amino-acid GHRH analog carrying a trans-3-hexenoyl moiety for DPP-4 resistance, binding GHRH receptors on pituitary somatotrophs to stimulate endogenous GH release, which acts through the GH receptor and IGF-1 to drive lipolysis and preserve lean mass. Critically, Tesamorelin stimulates the pituitary directly and does not rely on nutrient absorption or GI endocrine signals, so it can be dosed at night alongside Retatrutide without blunting GH release. Retatrutide slows gastric emptying (process one) but does not touch pituitary stimulation (process two), so the two levers remain independent. Three levers operate at once: Retatrutide drives fat loss via triple receptor agonism, appetite suppression, and hepatic thermogenesis; Tesamorelin drives lipolysis and lean mass preservation via GH and IGF-1; and the combination preserves muscle while accelerating fat loss.
Retatrutide handles the gut-driven lever — appetite, gastric emptying, hepatic thermogenesis — while Tesamorelin handles the pituitary-driven lever of GH and IGF-1. Because the two processes run on separate physiology, they stack without one blunting the other, preserving muscle as fat is stripped away.
Fat Mobilization
Tesamorelin + AOD-9604 — two non-overlapping arms of fat metabolism.
Two arms of fat metabolism. Tesamorelin works the pituitary GH axis; AOD-9604 works the adrenergic lipolysis axis. They don't compete for the same receptor, so they add up.
Tesamorelin is a GHRH analog that stimulates pituitary GH release, which drives lipolysis through the GH receptor and IGF-1 and preserves lean mass. AOD-9604 is a modified C-terminal fragment (amino acids 177–191) of human growth hormone that directly activates beta-3 adrenergic receptors (β3-AR) on adipocytes to stimulate hormone-sensitive lipase (HSL) and drive lipolysis, without affecting blood glucose or IGF-1. The two agents act through non-overlapping pathways — the pituitary GH axis versus direct adrenergic lipolysis on the fat cell — so they combine additively for fat mobilization without competing for the same receptor. Because AOD-9604 spares glucose and IGF-1, it does not introduce the metabolic noise that would otherwise blunt Tesamorelin's GH-driven effects.
Tesamorelin mobilizes fat from the top down through the pituitary GH/IGF-1 axis; AOD-9604 mobilizes fat from the bottom up by directly triggering β3-AR and HSL on the adipocyte. Two arms pulling on separate ropes of the same fat mass, with no receptor overlap to dampen either one.